Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull...

Area of Science:

• Immunology
• Vaccinology
• Preclinical Models

Background:

• Developing effective vaccines is hindered by preclinical models that fail to predict human immune responses.
• This leads to increased costs and delays in clinical studies.
• A reliable preclinical model is crucial for early vaccine candidate selection.

Purpose of the Study:

• To develop and evaluate a novel humanized mouse model, Hu-SPL-NSG, for predicting human immune responses.
• To assess the immunogenicity of two malaria vaccine candidates, LSA3-Full Length (LSA3-FL) and LSA3-729, using this model.
• To compare the predictive accuracy of the Hu-SPL-NSG model with previous preclinical and clinical findings.

Main Methods:

• Human spleen cells were engrafted into immunodeficient NOD-SCID-IL-2rγnull (NSG) mice to create the Hu-SPL-NSG model.
• Mice were immunized with LSA3-FL or LSA3-729, adjuvanted with montanide ISA720.
• Humoral and cellular immune responses were analyzed.
• Results were validated across multiple human donor cell groups.

Main Results:

• The shorter LSA3-729 construct induced protective human antibodies and a T-helper type 1 response.
• The LSA3-FL construct did not elicit a protective response and induced T-regulatory responses from specific antigenic regions.
• The Hu-SPL-NSG model's findings mirrored clinical outcomes for LSA3-FL and successfully predicted LSA3-729's efficacy.
• The model avoided limitations like graft-versus-host reactions seen in other humanized mice.

Conclusions:

• The Hu-SPL-NSG model is a relevant and cost-effective tool for predicting human immune responses to vaccine candidates.
• It offers advantages over existing humanized mouse models by avoiding common limitations.
• The study identifies LSA3-729 as a more promising malaria vaccine candidate for further development.